Send to:

Choose Destination
See comment in PubMed Commons below
Oral Maxillofac Surg Clin North Am. 2007 May;19(2):199-206, vi.

Osteonecrosis and bisphosphonates in oral and maxillofacial surgery.

Author information

  • 1Division of Oral and Maxillofacial Surgery, Long Island Jewish Medical Center, 270-05 76th Ave., New Hyde Park, NY 11040, USA.


Bisphosphonates are a class of compounds approved for the treatment of multiple myeloma, hypercalcemia of malignancy, osteolytic lesions of metastatic disease, Paget's disease, and most commonly, osteoporosis. Recently, these drugs have been associated with a new clinical entity, bisphosphonate related osteonecrosis (BRON) which is characterized by jaw necrosis that typically presents following dentoalveolar surgery. The pathogenesis for this complication appears to related to bisphosphonate mediated inhibition of osteoclast function and normal bone remodeling. This complication can have a significant impact on the quality of life for those patients with advanced stages of necrosis.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk